Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Saw, RP-M
dc.contributor.author	Armstrong, B
dc.contributor.author	Mason, RS
dc.contributor.author	Morton, RL
dc.contributor.author	Shannon, KF
dc.contributor.author	Spillane, AJ
dc.contributor.author	Stretch, JR
dc.contributor.author	Thompson, JF
dc.date.accessioned	2022-08-23T01:43:00Z
dc.date.available	2022-08-23T01:43:00Z
dc.date.issued	2014	en
dc.identifier.uri	https://hdl.handle.net/2123/29440
dc.description.abstract	Patients with primary cutaneous melanomas that are ulcerated and >2 mm in thickness, >4 mm in thickness and those with nodal micrometastases at diagnosis, have few options for adjuvant treatment. Recent studies have suggested a role for vitamin D to delay melanoma recurrence and improve overall prognosis.	en
dc.language.iso	en	en
dc.publisher	BMC Cancer	en
dc.rights	Creative Commons Attribution 4.0	en
dc.subject	melanoma	en
dc.subject	randomised trial	en
dc.subject	vitamin D	en
dc.subject	safety	en
dc.subject	toxicity	en
dc.subject	recurrence	en
dc.title	Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D)	en
dc.type	Article	en
dc.subject.asrc	1117 Public Health and Health Services	en
dc.identifier.doi	10.1186/1471-2407-14-780
dc.type.pubtype	Publisher's version	en
usyd.faculty	SeS faculties schools::Faculty of Medicine and Health::NHMRC Clinical Trials Centre	en
workflow.metadata.only	No	en